IL17A and cancer: Stromal cells in prostate cancer exposed to the topoisomerase II inhibitor Mitoxantrone, a genotoxic agent, secreted Wnt16B, which in turn promoted the proliferation and invasion of cancer cells [89], and in colorectal cancer, FOLFOX chemotherapy exposure led to the enrichment of IL-17A–producing CAF, resulting in enhanced tumor growth and proliferation of cancer-initiating cells [90].